• New design
• Enhanced Ergonomics Series mode: Press the measurement button for a sustained period of time (more than 2 seconds) and the tonometer will take six samples in rapid succession
Single mode: In this mode, the measurement button must be pressed each time to initiate measurement (six samples = a complete measurement cycle)
• Easy-to-use • Quick, effective routine barely noticeable by the patient • Revolutionizes early glaucoma detection and control • No topical anaesthetics or disinfection needed • Disposable probe touches the cornea very lightly • Suitable also for non-compliant patients and children • Proven accurate by several independent studies • Truly portable
• The probe touches the cornea very gently • Measurement takes place in 0.1 seconds • Corneal reflex after 0.2 seconds • Measurement of motion parameters • To be repeated 6 times in order to minimize deviation and to produce a calculated measurement value • Whole procedure (6x both eyes) takes about one minute  130 patients  Compared IOP measured using Icare HOME by patient to IOP measured by Icare HOME unit and GAT by an OMD  98%, (128/130) were able to correctly conduct self-measurement  Mean IOP
• GAT: 12.2±2.8 mm Hg • HOME patient 12.8±3.7 mm Hg • HOME OMD 13.1±3.8 mm Hg
Takagi, D; Sawada, A et al Glaucoma: July 2017; 26(7): 613-618  The IOP difference between the HOMEp and GAT measurements was >3 mm Hg in 9.4% of cases (12/128), and >5 mm Hg in 2.3% of cases (3/128).
 Difference between HOMEp and GAT values was significantly increased with increasing CCT (P=0.024), indicating that a 10% increase in CCT predicted a 1.2% increase in the difference.
 Conclusion: The Icare HOME tonometer is feasible for use in self-monitoring of IOP. Icare HOME tonometry measurements tend to overestimate IOP relative to GAT measurements. 7/11/2017 8  100 glaucomatous eyes with 24-2 MD < 6dB
• Tested with 10-2  As many abnormal 10-2 hemifields (53%) as abnormal 24-2 hemifields (59%).
 Of the eyes with normal 24-2 hemifields, 16% were classified as abnormal with the 10-2 test  Of the abnormal 10-2 hemifields, 68%, 8%, and 25% were arcuatelike, widespread, and other, respectively  Superior VF defects were deeper and closer to fixation than those in the inferior VF  Mean global progression rate was significantly greater in 10-2 analysis (-0.40±0.51 dB/yr) than in 24-2 analysis (-0.23 ± 0.28 dB/yr) (P=0.01).
 Within the central 10 degrees of VF, 10-2 analysis detected significantly more progressing eyes than 24-2 analysis (24 vs. 7 eyes; P<0.001).
 Within the central 10 degrees, mean localized progression rate (-1.3 vs. -0.4 dB/yr) and mean number of progressing points (2.5 vs. 0.5) were significantly greater in 10-2 than in 24-2 analyses (10-2 vs. 24-2; all P<0.001).
 In glaucoma patients with an IPFS, the 10-2 VF detects more progressing eyes than the 24-2 VF, suggesting that closer surveillance of the central VF using 10-2 VF is warranted in these eyes. 
Baltimore Eye Survey 
n=18
 Results:
 Diurnal period, the mean IOP under brinzolamide or timolol add-on treatment was significantly lower than the baseline IOP in both the sitting and supine positions. There was no statistical difference between the 2 add-on treatments.  Nocturnal period, the supine IOP under brinzolamide add-on treatment was significantly lower than both the baseline and the timolol addon treatment.  There was no difference in nocturnal IOP between the timolol add-on treatment and the baseline. • latanoprost and brinzolamide=19.8%, latanoprost=14.1%, P<0.001
 Nocturnal mean IOP reduction:
• latanoprost and brinzolamide=13.4%, latanoprost=10.0%, P<0.05  0.1% brimonidine TID for 4 weeks  Results: The diurnal IOP mean was significantly lower than the baseline IOP in both the sitting and supine positions.
 No statistically significant change in IOP under the brimonidine treatment from the baseline during the nocturnal period.
Liu JH et al AJO 2010
Liu JH et al AJO 2010
 Cross over study of effect of different classes of IOP lowering meds on DPP
• PGA and CAI significantly increased DPP at all time points • Beta-blocker significantly increased DPP from 4AM to 4PM but had no effect at other times • Alpha agonist significantly reduced DPP at multiple time points, primarily due to significant decrease in systemic BP • Comment: The impact of eye drop related changes in OBF on the development and progress of glaucoma is unknown.
• Some data support increased blood flow and the enhancement of OBF regulation with CAI's. These appear to exceed what one would expect from their ocular hypotensive effect alone.
 Compared the diurnal and nocturnal effects of latanoprostene bunod with timolol maleate 0.5% solution on IOP and ocular perfusion pressure(OPP)  25 patients with OHTN or early OAG  Baseline IOP and blood pressure were measured in a sleep lab Q2H in the sitting and supine positions during the 16-hour diurnal/ wake period and in the supine position during the 8-hour nocturnal/sleep period  Subjects were randomly assigned to bilateral treatments of latanoprostene at 8 PM or timolol at 8 AM and 8 PM.  The second laboratory recording occurred after the 4-week treatment. Subjects were crossed over to the comparator treatment for 4 weeks before the third laboratory recording.  Mean IOP and calculated ocular perfusion pressure were compared for the diurnal and nocturnal periods.  There was a significant IOP reduction with the latanoprostene bunod treatment during the diurnal/wake period and during the nocturnal/sleep period compared to baseline. The nocturnal IOP-lowering effect of latanoprostene bunod appeared less than the effect during the diurnal period. Posture was not a factor for the relatively smaller nocturnal IOPlowering effect, since both the 24-hour supine IOP profile and the 24-hour habitual IOP profile showed comparable diurnal vs nocturnal IOP reductions from the baselines.
 Low OPP has been proposed as a risk factor for glaucomatous damages. Alteration of OPP pressure can occur by changes in BP and/or IOP. Although the mean arterial blood pressure did not change significantly under either test agent of latanoprostene bunod or timolol over the 24-hour period, the latanoprostene treatment increased the diurnal OPP over the baseline owing to a significant IOP reduction during the diurnal period. Treatment with timolol showed no significant effect on diurnal OPP, probably because of a relatively smaller IOP reduction. Results also showed a greater nocturnal OPP under the latanoprostene treatment compared to the timolol treatment, reflecting the smaller effect of timolol on IOP lowering combined with some reduction in MABP. The latanoprostene treatment is expected to be more beneficial than the timolol treatment if one considers the difference in ocular perfusion pressure during the day and at night.
 Treatment with latanoprostene bunod 0.024% once daily resulted in IOP lowering during the diurnal/wake period as well as during the nocturnal/sleep period. Treatment with latanoprostene bunod showed a greater nocturnal IOP-lowering efficacy compared to treatment with timolol 0.5% solution twice daily. Latanoprostene bunod treatment significantly increased diurnal ocular perfusion pressure from the baseline. Ocular perfusion pressure during the nocturnal period was higher under latanoprostene bunod treatment than under timolol treatment. Designed to be used in conjunction with cataract surgery to safely and effectively reduce IOP while facilitating the eye's natural outflow in mild to moderate OAG patients.
• Lasting Outcomes Through 3 Years (T. Neuhann)
• Consecutive series of 62 eyes: decision to implant based on patient desire to reduce topical meds and intent to offer surgical treatment with favorable safety profile
• In consistent cohort of 39 eyes followed through 36 months, mean IOP was 14.9 mm Hg, a 36% reduction
• Over same period, mean number of topical meds declined from 1.9 to 0.3 or 86%
 Prospective, non-comparative, uncontrolled, non-randomized, interventional case series Innovative approach
• Requires a small corneal incision 1
• The first ab-interno approach to create a new pathway for aqueous flow from the anterior chamber to the subconjunctival space in refractory glaucoma patients 1
• XEN ® is the first procedure that creates a low-lying, ab-interno bleb in refractory glaucoma 2
Minimally Invasive Inserted using the XEN ® Injector via an ab-interno approach, through a small corneal incision. 1
In the clinical investigation, standard ophthalmic surgery techniques, viscoelastic, and mitomycin C (0.2 mg/mL) were used before injection. 
